BioArctic will create a new drug candidate using its BrainTransporter platform and Lilly’s molecule.

Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and ...

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment ...

BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer's ...

STOCKHOLM, Feb. 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated with ...

BioArctic AB announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s proprietary ...

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi Iqlik was launched for weekly maintenance dosing and Eisai ...

BioArctic AB (publ), a Swedish research-based biopharma company, announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a ...

STOCKHOLM, April 21, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company's website. The ...

"Each year of preserved function is of great significance for patients and their families" The first quarter of 2026 was characterized by regulatory progress and strong financial performance, driven ...

STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the ...

STOCKHOLM--(BUSINESS WIRE)--BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize ...